Hidemitsu Kitamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/960173/publications.pdf

Version: 2024-02-01

24 papers 2,073 citations

16 h-index 642732 23 g-index

24 all docs

24 docs citations

times ranked

24

3394 citing authors

#	Article	IF	Citations
1	The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells. Journal of Experimental Medicine, 1999, 189, 1121-1128.	8.5	588
2	IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation. Journal of Immunology, 2004, 173, 3844-3854.	0.8	444
3	IL-6-STAT3 Controls Intracellular MHC Class II $\hat{l}\pm\hat{l}^2$ Dimer Level through Cathepsin S Activity in Dendritic Cells. Immunity, 2005, 23, 491-502.	14.3	191
4	Interleukinâ€6/ <scp>STAT</scp> 3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Science, 2017, 108, 1947-1952.	3.9	189
5	Antiâ€∢scp>lLâ€6 receptor m <scp>A</scp> b eliminates myeloidâ€derived suppressor cells and inhibits tumor growth by enhancing <scp>T</scp> â€cell responses. European Journal of Immunology, 2012, 42, 2060-2072.	2.9	119
6	IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells. Cancer Immunology, Immunotherapy, 2016, 65, 193-204.	4.2	83
7	The Key Role of IL-6–Arginase Cascade for Inducing Dendritic Cell–Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice. Journal of Immunology, 2013, 190, 812-820.	0.8	65
8	Lack of interleukinâ \in 6 in the tumor microenvironment augments typeâ \in 1 immunity and increases the efficacy of cancer immunotherapy. Cancer Science, 2017, 108, 1959-1966.	3.9	61
9	IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells. Cancer Immunology Research, 2019, 7, 1944-1957.	3.4	61
10	First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Science, 2012, 103, 150-153.	3.9	53
11	MicroRNA 16-5p is upregulated in calorie-restricted mice and modulates inflammatory cytokines of macrophages. Gene, 2020, 725, 144191.	2.2	31
12	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. Journal of Experimental Medicine, 2021, 218, .	8.5	27
13	IFNâ€Î³ elevates airway hyperâ€responsiveness via upâ€regulation of neurokinin A/neurokininâ€2 receptor signaling in a severe asthma model. European Journal of Immunology, 2012, 42, 393-402.	2.9	25
14	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunology Letters, 2014, 161, 20-30.	2.5	24
15	Neuropeptide Signaling Activates Dendritic Cell-Mediated Type 1 Immune Responses through Neurokinin-2 Receptor. Journal of Immunology, 2012, 188, 4200-4208.	0.8	22
16	IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. Scientific Reports, 2015, 5, 13650.	3.3	18
17	Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells. Journal of Allergy and Clinical Immunology, 2015, 136, 1690-1694.	2.9	14
18	Ecrg4 contributes to the anti-glioma immunosurveillance through type-l interferon signaling. Oncolmmunology, 2016, 5, e1242547.	4.6	14

#	Article	IF	CITATION
19	Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): Preparation and immunological analysis of vaccine efficacy. Immunology Letters, 2015, 163, 102-112.	2.5	10
20	L-Type Calcium Channel-Mediated Zinc Wave Is Involved in the Regulation of IL-6 by Stimulating Non-IgE with LPS and IL-33 in Mast Cells and Dendritic Cells. Biological and Pharmaceutical Bulletin, 2019, 42, 87-93.	1.4	10
21	Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. Immunology Letters, 2014, 158, 175-182.	2.5	9
22	Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. Cancer Immunology, Immunotherapy, 2022, 71, 889-903.	4.2	8
23	<scp>IFN</scp> â€Î±/βâ€mediated <scp>NK2R</scp> expression is related to the malignancy of colon cancer cells. Cancer Science, 2022, , .	3.9	7
24	Inhibition of diacylglycerol kinase alpha to augment antitumor effector T cells in tumor-bearing host Journal of Clinical Oncology, 2019, 37, 293-293.	1.6	0